Exacompta - Clairefontaine (XPAR:ALEXA) Research & Development: €0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALEXA Exacompta - Clairefontaine SA XPAR:ALEXA
86 GF Score
Price €170.00
GF Value €144.70
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exacompta - Clairefontaine Research & Development?

Exacompta - Clairefontaine XPAR:ALEXA +3.66% 86 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates XPAR:ALEXA with a GF Score™ of 86/100 and a GF Value™ of €144.70 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Exacompta - Clairefontaine's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

Exacompta - Clairefontaine  (XPAR:ALEXA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Exacompta - Clairefontaine Research & Development Related Terms

Exacompta - Clairefontaine Research & Development Historical Data

* Premium members only.

The historical data trend for Exacompta - Clairefontaine's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exacompta - Clairefontaine Research & Development Chart

Exacompta - Clairefontaine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Exacompta - Clairefontaine Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALEXA
86GF Score
Exacompta - Clairefontaine SA XPAR:ALEXA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exacompta - Clairefontaine Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
Exacompta - Clairefontaine (XPAR:ALEXA) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Exacompta - Clairefontaine and its competitors.
Is Exacompta - Clairefontaine's Research & Development too high?
Exacompta - Clairefontaine's current Research & Development is €0.0 Mil. Overall, Exacompta - Clairefontaine has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exacompta - Clairefontaine's Research & Development compare to competitors?
Exacompta - Clairefontaine's Research & Development of €0.0 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Industrial Products company?
A good Research & Development depends on the Industrial Products industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Exacompta - Clairefontaine and its competitors. Exacompta - Clairefontaine's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exacompta - Clairefontaine stock overvalued right now?
Based on GuruFocus' analysis, Exacompta - Clairefontaine (XPAR:ALEXA) is currently considered Modestly Overvalued. The stock's GF Value™ is €144.70, compared to a current price of €170.00 — trading 17.5% above its estimated fair value. The current Research & Development is €0.0 Mil. Exacompta - Clairefontaine's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Exacompta - Clairefontaine (XPAR:ALEXA), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exacompta - Clairefontaine (XPAR:ALEXA) Overvalued in 2026?

Based on GuruFocus' analysis, Exacompta - Clairefontaine stock appears to be overvalued. The current stock price of €170.00 is trading 17.5% above its estimated GF Value™ of €144.70. GuruFocus considers Exacompta - Clairefontaine to be Modestly Overvalued.

Key valuation signals for XPAR:ALEXA:

  • Research & Development: €0.0 Mil
  • GF Value™: €144.70 vs. price of €170.00 (17.5% above fair value)
  • GF Score™: 86/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALEXA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exacompta - Clairefontaine Business Description

Address 19, rue de l’Abbaye, Etival-Clairefontaine, Etival Clairefontaine, FRA, 88480
Exacompta - Clairefontaine SA is a France-based manufacturer of paper products, stationery, and office supplies. The group's operating segments are Paper and Processing. The paper segment includes the production, finishing, and formatting of the paper. The processing segment includes the manufacture of stationery, office and filing items, and digital photos. The company's primary brand names include Exacompta and Clairefontaine. The Exacompta brand offers a portfolio of record books, notebooks, copy pads, record cards, computer paper, pocket diaries, and filing products, whereas exercise books, school paper, envelopes, and copier paper are marketed under the Clairefontaine brand and manufactured by the Papeteries de Clairefontaine subsidiary.
86GF Score

Get the complete analysis for XPAR:ALEXA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€170.00
Price
€144.70
GF Value